Gsk (GLAXF) Goodwill & Intangibles (2009 - 2026)
Gsk (GLAXF) recorded quarterly Goodwill & Intangibles of $34.3 billion in Q1 2026, up 8.43% quarter-over-quarter from $31.6 billion in Q4 2025, and up 17.39% on a YoY basis from $29.2 billion in Q1 2025.
Gsk (GLAXF) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Gsk's Goodwill & Intangibles history runs 18 years deep, the most recent figure standing at $34.3 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 17.39% year-over-year to $34.3 billion; the TTM figure through Mar 2026 stood at $34.3 billion (up 17.39% YoY), while the FY2025 annual figure was $31.3 billion, up 8.97% from the prior year.
- Goodwill & Intangibles was $34.3 billion for Q1 2026 at Gsk, up from $31.6 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $37.2 billion in Q1 2022 to a low of $21.8 billion in Q2 2022.
- Historically, Goodwill & Intangibles has averaged $28.8 billion across 5 years, with a median of $28.3 billion in 2024.
- The sharpest annual moves came in 2022 and 2023: Goodwill & Intangibles plunged 60.86% in 2022, then advanced 27.95% in 2023.
- A 5-year view of Goodwill & Intangibles shows it stood at $25.1 billion in 2022, then gained by 6.88% to $26.8 billion in 2023, then gained by 7.81% to $28.9 billion in 2024, then rose by 9.48% to $31.6 billion in 2025, then increased by 8.43% to $34.3 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $34.3 billion (Q1 2026), $31.6 billion (Q4 2025), and $32.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Gsk | - | - | 7.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.28 Bn |
| Dec 31, 2025 | 31.61 Bn |
| Sep 30, 2025 | 32.36 Bn |
| Jun 30, 2025 | 29.50 Bn |
| Mar 31, 2025 | 29.20 Bn |
| Dec 31, 2024 | 28.87 Bn |
| Sep 30, 2024 | 28.18 Bn |
| Jun 30, 2024 | 28.32 Bn |
| Mar 31, 2024 | 28.73 Bn |
| Dec 31, 2023 | 26.78 Bn |
| Sep 30, 2023 | 28.21 Bn |
| Jun 30, 2023 | 27.84 Bn |
| Mar 31, 2023 | 25.55 Bn |
| Dec 31, 2022 | 25.06 Bn |
| Sep 30, 2022 | 26.85 Bn |
| Jun 30, 2022 | 21.76 Bn |
| Mar 31, 2022 | 37.16 Bn |
| Dec 31, 2021 | 54.77 Bn |
| Sep 30, 2021 | 56.28 Bn |
| Jun 30, 2021 | 55.58 Bn |